Investment
Features
FeesSafety
Academy
More
Pluang+

Compare NIO Inc. (NIO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

NIO Inc.Trade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

NIO Inc. vs Recursion Pharmaceuticals Inc — how do they compare? NIO Inc. trades at $4.81 (market cap $12.55B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: NIO Inc. is far larger — about 8.2× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

NIORXRX
Market Cap
$12.55B$1.53B
Sector
Consumer CyclicalHealth
52-Week High
$7.89$6.79
52-Week Low
$4.44$2.84
Enterprise Value
$11.78B$946.50M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

NIO Inc.

NIO trades at $4.79, down 1.84% with bearish technical signals despite strong delivery growth. The company shows improving fundamentals with revenue reaching $87.49B in 2025 and narrowing losses, though it remains unprofitable with negative cash flow. Analyst sentiment is mixed with 54% buy ratings but technical indicators show selling pressure. Recent vehicle deliveries surged 62.9% year-over-year in June 2026, providing optimism for margin improvement.

NIO presents a high-risk opportunity with significant growth potential but persistent profitability challenges. The stock offers exposure to China's EV market expansion but faces execution risks and competitive pressures. While delivery momentum is strong, investors must weigh the company's cash burn against its market position and Goldman Sachs' recent upgrade to buy with $7 target.

Recursion Pharmaceuticals Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About NIO Inc.

NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.

Read more on NIO

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX